Liu CJ, et al. - Given that patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are at risk of developing adverse outcomes, researchers intended to determine the role of fibrosis-4 index (FIB-4), a simple liver fibrosis stage biomarker, in predicting the clinical outcomes. One hundred fifty-two non-cirrhotic patients with dual chronic HCV and HBV infection were retrospectively enrolled in this analysis. Even in patients receiving pegylated interferon/ribavirin therapy, FIB-4 index helps identify patients at risk of developing adverse events in Taiwanese patients co-infected with HCV and HBV.